Avalon, Blogging and Capital - Southern California Tech Central

Avalon Funds Internet Comedy Site Cheezburger

socalTECH

JANUARY 17, 2011

San Diego-based venture capital firm Avalon Ventures has boosted an Internet web site publisher known for its humorous, captioned pictures of cats and use of Internet memes, Cheezburger. which features "LOLcats", funny pictures of cats with humorous captions, and FAIL Blog , a site which highlights "fails".

Avalon

Avalon Sites Funding San Diego

Cheezburger Deal Spawned Out Of LA's TwiistUp

socalTECH

JANUARY 18, 2011

and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.

Twiistup

Twiistup Avalon San Diego Conference

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup

Xconomy

SEPTEMBER 27, 2016

San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. 9/27/16, 2:09 p.m. Bregua Corp.,

Avalon

Avalon Funding Startup San Diego

After Investing, GSK to Buy Out Celiac Drug Developer Sitari Pharma

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon

Avalon Invest Southern California Develop

Intel Deepens Move into Sports Tech with SportStream Investment

Xconomy

NOVEMBER 19, 2017

million in a Series A round that includes Intel Capital as an investor. According to a recent ScoreStream statement , San Diego’s Avalon Ventures, a longtime ScoreStream investor, led the round, and was joined by Sinclair Broadcasting, Verizon Ventures, and R/GA Ventures, the investment arm of the advertising agency R/GA.

Avalon

Avalon Invest Social Media Media

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego.

Avalon

Avalon San Diego Study Invest

Dauntless Takes Flight with New Business Model for Starting Biotechs

Xconomy

JULY 20, 2016

Then came COI Pharmaceuticals , the shared “community of innovation” for startup biotechs established by San Diego’s Avalon Ventures as part of its partnership with GlaxoSmithKline. It’s a little like what Avalon is doing. We are taking capital as needed, not sooner.”. But it’s structured differently.

San Diego

San Diego Avalon Outsource Development Newsletter

Synthorx Raises $10M to Expand Use of Synthetic DNA in Biologics

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego

San Diego Avalon Research Examples

An Homage to Larry Bock, Who Had God’s Hand on His Shoulder

Xconomy

JULY 10, 2016

It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. After talking with dozens of scientists, he would have a list of five or six names, and those were the people he would recruit for his startup. Larry and Kevin Kinsella had a really good partnership,” Diane Bock said. They had a lot of fun.”.

San Diego

San Diego Startup Avalon Venture Capital

Synthorx Gets $131M In Upsized IPO For Synthetic Biology Drugs

Xconomy

DECEMBER 7, 2018

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

Technology

Technology Develop Development San Diego

Plug and Play San Diego Finds Home in New Downtown Works Space

Xconomy

OCTOBER 30, 2016

I have a vast network of friends in San Diego and Mexico City who are serial investors,” said Cohen, who is a principal at Walket Capital and affiliated with LM Advisors, a San Diego investment firm with over $1.3 (The other partners are Edward Adato and Daniel Schwarzblat.). “I billion under management. Downtown Works Interior.

San Diego

San Diego Incubator Avalon Mentor

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs

Xconomy

APRIL 30, 2018

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

Technology

Technology Venture Capital San Diego Avalon

Synthorx Files for IPO to Advance Enhanced Cytokine Drugs

Xconomy

NOVEMBER 14, 2018

Synthetic biology company Synthorx is laying plans for an initial public offering to raise money to advance its suite of enhanced cytokine drugs.

San Diego

San Diego Product Develop Development

No Vital Signs Apparent at Wireless Health Specialist Awarepoint

Xconomy

JUNE 6, 2018

Awarepoint, the San Diego healthtech startup that specialized in real-time location systems for tracking medical equipment and people in hospitals and clinics, has gone 404. That’s the error code message that comes up for a website that no longer exists.

Tips

Tips San Diego Startup Avalon

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

Xconomy

JANUARY 26, 2017

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders.

Marketing

Marketing San Diego Invest Help

Southern California Tech Central

Avalon Funds Internet Comedy Site Cheezburger

Cheezburger Deal Spawned Out Of LA's TwiistUp

Trending Sources

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup

After Investing, GSK to Buy Out Celiac Drug Developer Sitari Pharma

Intel Deepens Move into Sports Tech with SportStream Investment

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

Dauntless Takes Flight with New Business Model for Starting Biotechs

Synthorx Raises $10M to Expand Use of Synthetic DNA in Biologics

An Homage to Larry Bock, Who Had God’s Hand on His Shoulder

Synthorx Gets $131M In Upsized IPO For Synthetic Biology Drugs

Plug and Play San Diego Finds Home in New Downtown Works Space

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs

Synthorx Files for IPO to Advance Enhanced Cytokine Drugs

No Vital Signs Apparent at Wireless Health Specialist Awarepoint

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

Stay Connected